Parexel and Palantir Forge Deeper Partnership to Enhance Clinical Trials with AI

Parexel and Palantir Technologies have unveiled an ambitious multi-year strategic partnership aimed at harnessing the power of artificial intelligence (AI) to elevate the delivery of clinical trials for Parexel's clientele. This collaboration sees Parexel integrating Palantir's Foundry and Artificial Intelligence Platform (AIP) into its clinical data platform, marking a significant leap forward in leveraging cutting-edge technology to enhance trial execution.

Elevating Clinical Trial Execution with AI

The partnership centers on enhancing Parexel's Precision Pathway, an end-to-end operational strategy that prioritizes the utilization of clean data in clinical trials. By leveraging Palantir's software, Precision Pathway will create an integrated digital environment to automate manual processes, enhance data discoverability, extract insights from past trials, and streamline collaboration among scientific and operational teams and their partners.

Jonathan Shough, Parexel's Chief Information Officer, expressed excitement about the collaboration, stating, "We're thrilled to expand our collaboration with Palantir—a leader in artificial intelligence technology—as we build on our application of AI to further improve clinical trial execution and advance our offerings in real-world evidence, advanced analytics, and health outcomes."

Empowering Customers with Quality Data

Parexel's customers will benefit from access to high-quality, validated data facilitated by Foundry and AIP technology. This ensures transparency throughout studies and accelerates timelines from planning to submission, ultimately enhancing efficiency and effectiveness in clinical trial processes.